Pulmocide is a developer of new drugs for respiratory diseases, focusing on the development of drugs for respiratory diseases. Pulmocide announced it has raised $52 million in an extended Series C round led by new investors Pictet Alternative Advisors and Vivo Capital. Existing investors SV Health Investors, Jeito Capital, SR One, IP Group plc, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc., Adjuvant Capital, Asahi Kasei Pharma, Longwood Fund and Cystic Fibrosis Foundation also participate.
This article is transferred from: https://www.itjuzi.com/investevent/13708610
This site is only for collection, and the copyright belongs to the original author.